NanoViricides, Inc. (NYSE American: NNVC) announced that CEO Dr. Anil Diwan discussed major advances in the company’s antiviral research during a video interview with Proactive, available at https://youtu.be/m_3Yk4_832E. Dr. Diwan reported that NanoViricides’ lead candidate, NV-387, showed strong anti-Measles activity in both cell culture and humanized animal models, extending survival by 130% and protecting lung tissue in severe infection stages.
With no approved Measles treatments currently available, the findings underscore NV-387’s broad-spectrum potential. The drug has completed Phase I human trials with no reportable adverse events and is advancing to Phase II for MPox. NanoViricides is positioned to support FDA emergency use applications and investigator-initiated INDs for urgent Measles cases.
This development is significant because measles remains a serious global health threat, particularly in regions with low vaccination rates. The World Health Organization reported over 9 million measles cases and 128,000 deaths in 2021. Current treatment is limited to supportive care, and no antiviral therapies are approved. NV-387’s mechanism targets the virus directly, potentially reducing severity and transmission.
NanoViricides’ platform technology utilizes nanoviricide particles that mimic host cell receptors to bind and neutralize viruses. NV-387 has demonstrated broad-spectrum activity against multiple viruses, including SARS-CoV-2, influenza, and MPox. The company plans to file an Investigational New Drug application for MPox and pursue emergency use authorization for measles based on these promising results.
Dr. Diwan emphasized that NV-387’s safety profile is favorable, with no adverse events in Phase I. The drug’s ability to protect lung tissue is critical, as measles often leads to pneumonia, a major cause of death. The company is collaborating with academic institutions to advance clinical studies.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC.
